A323990 Stock Overview
Develops and sells cancer immune cell therapy products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Vaxcell-Bio Therapeutics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩10,280.00 |
| 52 Week High | ₩25,200.00 |
| 52 Week Low | ₩9,980.00 |
| Beta | 3.4 |
| 1 Month Change | 2.49% |
| 3 Month Change | -19.50% |
| 1 Year Change | -47.28% |
| 3 Year Change | -63.98% |
| 5 Year Change | n/a |
| Change since IPO | 15.83% |
Recent News & Updates
We're Not Very Worried About Vaxcell-Bio Therapeutics' (KOSDAQ:323990) Cash Burn Rate
Nov 12
We Think Vaxcell-Bio Therapeutics (KOSDAQ:323990) Can Afford To Drive Business Growth
Jul 29We're Interested To See How Vaxcell-Bio Therapeutics (KOSDAQ:323990) Uses Its Cash Hoard To Grow
Apr 01Shareholder Returns
| A323990 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -4.1% | 2.7% | 0.5% |
| 1Y | -47.3% | 26.1% | -1.0% |
Return vs Industry: A323990 underperformed the KR Biotechs industry which returned 26.1% over the past year.
Return vs Market: A323990 underperformed the KR Market which returned -1% over the past year.
Price Volatility
| A323990 volatility | |
|---|---|
| A323990 Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A323990 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A323990's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | n/a | www.vaxcell-bio.com |
Vaxcell-Bio Therapeutics Co., Ltd. develops and sells cancer immune cell therapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea.
Vaxcell-Bio Therapeutics Co., Ltd. Fundamentals Summary
| A323990 fundamental statistics | |
|---|---|
| Market cap | ₩236.37b |
| Earnings (TTM) | -₩10.43b |
| Revenue (TTM) | ₩69.60m |
3,396x
P/S Ratio-22.7x
P/E RatioIs A323990 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A323990 income statement (TTM) | |
|---|---|
| Revenue | ₩69.60m |
| Cost of Revenue | ₩35.33m |
| Gross Profit | ₩34.27m |
| Other Expenses | ₩10.47b |
| Earnings | -₩10.43b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -453.72 |
| Gross Margin | 49.24% |
| Net Profit Margin | -14,989.18% |
| Debt/Equity Ratio | 0% |
How did A323990 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/28 01:26 |
| End of Day Share Price | 2025/01/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vaxcell-Bio Therapeutics Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|